- Home
- SCWO vs CVM Comparison
SCWO vs CVM Comparison
Compare SCWO & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCWO | CVM |
|---|---|---|
| Founded | 2021 | 1983 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Environmental Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.2M | 32.4M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | SCWO | CVM |
|---|---|---|
| Price | $2.51 | $3.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.0K | 40.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.16 | $0.18 |
| 52 Week High | $3.55 | $13.48 |
Technical Indicators
Market Signals| Indicator | SCWO | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 35.94 |
| Support Level | $2.33 | $2.02 |
| Resistance Level | $3.10 | $6.71 |
| Average True Range (ATR) | 0.21 | 0.38 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 18.87 | 19.17 |
Price Performance
Historical ComparisonAbout SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.